Cryo-cell International (CCEL) Stock
Small company cord blood bank storing stem cells. Here's the price, business snapshot, and what's worth knowing about Cryo-cell International in August 2026.
Cryo-Cell International, Inc. (CCEL) is a small-cap company that operates in the cord blood and tissue banking industry, storing stem-cell rich biological material for potential future medical use. Investors should know it earns revenue from initial processing and recurring storage fees, giving it a subscription-like component to revenues, but growth depends on consumer awareness, referral networks and regulatory conditions. With a market capitalisation around $35m, CCEL is thinly traded and can be volatile; financial flexibility and access to capital may be ongoing considerations. The business is sensitive to healthcare regulations, competition from larger national banks, and technological or clinical advances that could change demand. For many investors this type of stock is speculative and may suit those with a higher risk tolerance and a long-term horizon. This is general educational information only, not personal financial advice; returns are not guaranteed and the value of equities can fall as well as rise.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Cryo-Cell's stock with a target price of $9, indicating possible growth.
Financial Health
Cryo-Cell International Inc is performing well, generating strong revenue and profit margins, with positive cash flow.
Dividend
Cryo-Cell International Inc's high dividend yield of 14.22% makes it an attractive option for income-focused investors. If you invested $1000 you would be paid $142.20 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Recurring Revenue Model
Processing fees plus annual storage create a subscription-like revenue stream, which can smooth income — though growth depends on new customer sign-ups and retention.
Niche Healthcare Service
Cord blood banking sits at the intersection of consumer health and biotech, with potential demand from future therapies — regulatory and scientific shifts can change the outlook.
Small-cap Dynamics
With a market cap around $35m, the stock can be volatile and thinly traded; this may suit higher-risk, long-term investors but increases capital and liquidity risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.